Five Core Pillars
The Macro Problem
Sickness Inflation & Polypharmacy Failures
"Healthcare spending is dominated by repetitive chronic care cycles, trial-and-error drug prescribing, and multi-drug polypharmacy that drains health system budgets and leaves patients dependent on lifetime medication."
ACOs and health systems lose millions annually to preventable adverse drug events, 30-day hospital readmissions, and non-responsive patient populations.
The Clinical Solution
Standardized Remission & Drug Off-Ramping
"BCG Health bridges traditional ethnobotanical wisdom with modern multi-omics research to keep patients in long-term clinical remission."
Pharmacogenomics (PGx) screening maps patient DNA to CYP450 metabolic pathways to identify adverse drug reactions and safely transition patients off end-of-life pharmaceuticals onto batch-tested, standardized botanicals — in tandem or as standalone health support.
Clinical Pilot & CPG Validation
The ADHD Whole-Food Nootropic Cohort
"We validate our lifestyle and CPG product fleet through targeted 5-individual research cohorts — starting with our ADHD executive function pilot."
A 4-Week Repeatable Whole Food Nootropic Diet uses blood-type profiling, BMI metrics, 100% home-cooked meal prep, and adaptogenic botanicals (Ashwagandha, Triphala, Bacopa) to stabilize dopamine baselines, improve cognitive focus, and replace synthetic stimulants.
Regulatory & Quality Control Moat
DSHEA Decoupling & USP <561>
"We transition from counterculture wellness roots to medical-grade clinical governance without the 10-year, $1B FDA drug approval risk."
A dual regulatory model — operating under DSHEA with structure-function claims for dietary supplements while enforcing USP <561> heavy metal / pesticide testing, GACP sourcing, and HPLC chemical fingerprinting for every batch.
A clinical council of physicians, pharmacologists, and population health experts holding DEA licenses and regional health system authority.
Dual-Engine Unit Economics
80%+ Gross Margin Cash Flywheel
"BCG Health operates a dual-channel cash engine with a programmatic Online Interest Indexing Engine and a blended True CAC model that out-performs paid-ad acquisition."
We programmatically index 10,000+ clinical long-tail search nodes (CYP450 pathways, herb-drug interactions, ADHD nootropic protocols, USP <561> testing) so high-intent patient and clinician traffic routes to BCG Health destinations instead of buying paid impressions. CAC decreases as indexed assets scale, inverting the paid-ad tax.
True CAC $14.50 per acquired customer. $52.00 initial AOV at 80% gross margin = $41.60 Day-1 gross profit. 12-month LTV $312.00 (4-week repeatable meal-prep + adaptogen auto-ships), yielding a 21.5 : 1 LTV/CAC ratio.
True CAC $145.00 per onboarded clinic. $1,260.00 initial AOV at 75% margin = $945 1st-order payback. $12,600 annual recurring revenue per clinic, yielding an 86.8 : 1 LTV/CAC ratio.
PGx-Guided Off-Ramp
CYP450 metabolic mapping flags adverse drug reactions before a single botanical is introduced.
Batch-Level CoA
USP <561> heavy-metal & pesticide testing, GACP sourcing, HPLC chemical fingerprinting — every batch.
Recurring Clinic Revenue
NPI-gated portal drives $12,600 ARR per clinic at 80%+ gross margin, acquired at $145 True CAC (86.8 : 1 LTV/CAC).
The 3 Questions Investors Ask
How do you get doctors to adopt this?
We offer clinicians a free 2-minute Clinical Risk Audit that exposes unmonitored herb-drug interaction risks in their polypharmacy patients. Once they see the risk, we onboard them onto our NPI-gated portal where they can prescribe batch-tested, USP-compliant botanicals with complete confidence.
What is your capital allocation plan for the initial $100k raise?
We deploy capital directly into patient remission networking events hosted across top Davidson County hospital locations, providing clinical samples, biosonification sound therapy, and physician consultations to build a nationwide donor and referral pipeline.
What is your 5-year exit strategy?
We scale B2B clinic portal accounts to $10M+ ARR, creating an attractive acquisition target for major nutraceutical conglomerates (e.g., Atrium Innovations, Nestlé Health Science) or health system analytics buyers following the Stratasan / Syntellis exit playbook.
Ready for the full deck?
Request the 1-page Investor Executive Summary or a custom financial model for your upcoming pitch.